Press Releases

There is a well-established master furniture maker in upstate New York named Jim. I know of Jim because he built the kitchen table in my parents’ house. He builds everything from scratch — kitchen tables, bureaus, custom cabinetry and more — all to exacting specifications. Each one of his pieces is just as much a work of art as it is a piece of functional furniture.
 

A few years ago, I had the opportunity to visit Jim’s workshop and see the environment in which he performs his craft. Located in a barn overlooking a hillside in a rural community... read post here.

Traditionally, building a portfolio of drug programs requires hundreds of millions of dollars and takes many years in the biopharmaceutical industry. The convergence of available biomedical data, affordable cloud computing, and advances in algorithms is now enabling companies to build these drug portfolios for an order of magnitude less money and in a fraction of the time it traditionally takes. This is precisely what twoXAR is doing. Using our artificial intelligence-driven drug discovery platform, we aim to find new, more effective treatments to benefit patients across therapeutic areas.

Today I am proud to share that we have assembled a group of high-quality global investors who will help us achieve this vision. Our Series A, which is led by SoftBank Ventures... read post here

At twoXAR we bring together a lot of disparate data to rapidly identify disease treatments. It’s through these different data that we gain our predictive power. However, more data isn’t always better — not if the new data is of poor quality. In other words, quantity doesn’t trump quality, and that’s because of a common data science saying: bad data in = bad data out. Because of this, we check the quality of our input data at multiple levels; some of this is a manual process, but we automate as much as possible.

In July’s post, (ML)²: Myths and Legends of Machine Learning, I touched on the messiness of real world data and mentioned quality control checks; here, I will expand on that with an example of one of the checks we use for gene expression data... read post here.

From Day 1, our vision at twoXAR has been to “improve health through computation”. We’ve taken many steps along this journey, such as collaborations with leading companies like Santen and breaking new ground in the path to more efficacious treatments in liver cancer. As we continue to build momentum and scale our aspirations to help as many patients as possible, we’re increasingly drawing upon the expertise of industry veterans to guide our strategic decision-making.

Given this, I’m pleased to announce the formation of twoXAR’s Business Advisory Board and welcome Judy Lewent, Jonathan MacQuitty, and Howie Rosen as we move forward... read post here.

Skepticism is (and should be) a vital part of any science; statistics and data science are no exception. Statistician George Box nicely summed it up when he said, “all models are wrong, but some are useful”. Box reminds us that statistical models are just that: models. A simplified representation of the real-world will always have shortcomings. But we shouldn’t forget the last bit of Box’s saying: “some [models] are useful”. Although challenging, carefully constructed statistical models can be extremely useful... read post here.

• Google Maps now predicts how difficult it will be to park near your destination based on the behavior of other users in the area.
• Airbnb uses attributes of its users and available properties to generate personalized search results that lead to higher booking rates.
• twoXAR is predicting new drug candidates outside of the wet lab using biomedical data.

These three accomplishments are all possible today because of machine learning... read post here.

twoXAR Co-Founder, Andrew M. Radin, discusses artificial intelligence in drug discovery.

twoXAR CEO, Andrew A. Radin, discusses artificial intelligence in drug discovery and how it's impacting the discovery of novel ophthalmology therapeutics.

twoXAR CEO, Andrew A. Radin, speaks on AI Applications for Identifying New Drug Candidates panel with Saurabh Saha and Ramesh Durvasula.

twoXAR Co-Founder, Andrew M. Radin, presents Discovering, Validating, & Launching First-In-Class Therapeutic Programs in 4 Months.

twoXAR Co-Founder, Andrew M. Radin, discusses artificial intelligence in drug discovery.

twoXAR Co-Founder, Andrew M. Radin, presents Partnering in AI-Driven Drug Development.

twoXAR CEO, Andrew A. Radin, is joined by GSK's John Baldoni & Nimbus's Mark Ashwell.

twoXAR CEO, Andrew A. Radin, presents What if new medications could be found in minutes instead of years?

twoXAR CEO, Andrew A. Radin, is joined by Jeff Kindler & Vijay Pande.